MapLight Therapeutics IPO reportedly well oversubscribed

MapLight Therapeutics Inc.'s (MPLT) Nasdaq IPO has attracted orders exceeding the available shares ahead of its scheduled pricing on October 26, according to a Bloomberg report on Monday.

The central nervous system disorders-focused biotech company is offering 14.75 million shares at $17 each to raise $250.8 million. The company expected to stop taking orders Thursday after markets close in New York.

Due to the federal government shutdown and MapLight seeking automatic effectiveness of its registration statement 20 days after filing terms on October 6, the offering is scheduled to price on October 26, according to a management presentation. The company may reconsider the use of automatic effectiveness if the federal government and SEC resume normal operations before that date.

Morgan Stanley, Jefferies Financial Group Inc., Leerink Partners and Stifel Financial Corp. are working on the offering.

You May Also Be Interested In

• First Advantage to join S&P SmallCap 600, replacing Kennedy-Wilson
• Genco board commits to limit rights agreement extensions to 12 months
• Sonida Senior Living (SNDA) files for 17.11M share offering by selling stockholders